It does not mean a fibromyalgia drug is close, that Huntington's drugs will work for fibromyalgia, or that anyone should ask about them. Readers who see eventual claims about genetic risk scores for fibromyalgia should ask which population the underlying data came from. The study does not quantify how much of an individual's risk it accounts for. What is new is identifying specific genetic regions and cell types. The strongest variant sits in HTT, the Huntington's gene, and another implicates GPR52, which regulates HTT and is already a Huntington's drug target.